An interventional study of Sponge Capsule in Barrett Esophagus and Esophageal Adenocarcinoma, sponsored by Mayo Clinic. Completed at 8 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Barrett Esophagus by Mayo Clinic — 6 open to participants now, 6 under way, none of them phase 3. Barrett Esophagus · Mayo Clinic.
Among the 40 studies in Barrett Esophagus by Mayo Clinic, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is one of 13 with no phase, and was the 34th registered.
312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.
Browse Barrett Esophagus studies →6 of the 40 studies in Barrett Esophagus by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22+
Mayo Clinic · Sites in United States
Ages 18–90
Mayo Clinic · Sites in United States
Ages 18–90
Mayo Clinic · Sites in United States
Ages 18–90
By country, each count listing its studies:
Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,526 is above the median of 62 across 187 interventional studies indexed under Barrett Esophagus.
Median enrollment 60 across the 19 interventional studies, 90 across the 21 observational. Of the 33 that completed or were terminated, 9 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
2 of the studies in Barrett Esophagus by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06071845Mayo ClinicAssessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples | 2027-06-01 |
| NCT07126535Mayo ClinicImpact of RFA on Esophageal Distensibility and Mucosal Impedance | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Barrett Esophagus by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
The sponge on a string (SOS) device will be safely administered by a non-physician such as a nurse. Novel discriminant methylated DNA markers will be assayed on esophageal cytology specimens obtained from the SOS device to enable detection in Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection.
Inclusion Criteria Aim1:
Gastroesophageal reflux disease defined by:
Exclusion Criteria Aim1 and Aim 3:
Previous history of:
Inclusion criteria Aim 2 and Aim 3:
Subjects with known or suspected BE (cases).
Subjects without known history of BE (controls).
Exclusion criteria Aim 2:
Subjects with known BE.
For subjects with or without known evidence of BE (on history or review of medical records):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
Device: Sponge Capsule
Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
Device: Sponge Capsule
Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
Device: Sponge Capsule
Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
Also known as: EsophaCap, Cytosponge
Aim 1 - Screening Population
To measure the positive and negative predictive value of the sponge capsule Barrett's esophagus test in a screening population.
Time frame: 5 years
Aim 2 - Case/Control Population BE Detection
Compare the sensitivity and specificity of a predetermined BE prediction algorithm for those with and without GERD and assess the influence of other covariates (age, sex, ever smoking, ethnicity and BMI) on this algorithm.
Time frame: 5 years
Aim 3 - Dysplasia Detection Sensitivity and Specificity
Measure the sensitivity and specificity of a predetermined MDM panel assayed on SOS specimens from BE patients identified in Aims 1 and 2, for the detection of HGD /EAC, using surveillance histology as the criterion standard.
Time frame: 5 years
Aim 1 - Screening Population Predictive Value
Compare positive predictive value and negative predictive value of the sponge capsule Barrett's Esophagus test between those with and without chronic GERD.
Time frame: 5 years
Aim 1 - Screening Population Safety and Tolerability of sponge capsule procedure
Safety and tolerability of the sponge capsule device in a screening population as measured by a Tolerability Questionnaire with sponge capsule procedure. Participants will rate their tolerability by rating questions using a scale of 0-10 (0 is none and 10 is severe or 0 is good and 10 is not good).
Time frame: 5 years
Aim 2 - Case/Control Population Sensitivity and Specificity
Validate specificity and sensitivity cut offs of a BE prediction algorithm in an independent patient cohort
Time frame: 5 years
Aim 3 - Dysplasia Detection Rate of Missed Dysplasia
Measure diagnostic uncertainty bias in the criterion standard, specifically, the rate of dysplasia missed by surveillance histology
Time frame: 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Nov 2025, 52 months.
Of 65 non-industry interventional studies with no phase under Barrett Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 108. This study's 52 months is close to that.
Counting every sponsor, half of 76 studies reached it within 45 months; a quarter within 23 and three quarters within 108.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2030 → Nov 2025 and completion Jul 2030 → Nov 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.